Overview

Safety and Efficacy of Albiglutide in Type 2 Diabetes

Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to determine the safety, tolerability and efficacy of albiglutide in the treatment of type 2 diabetes.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Glucagon-Like Peptide 1
Metformin
Pioglitazone
rGLP-1 protein
Criteria
Inclusion Criteria:

- type 2 diabetes

- BMI 20-45kg/m2

Exclusion Criteria:

- NYHA Class II to IV heart failure

- females who are pregnant, lactating, or less than 6 weeks post-partum